Biotechnology firm NurExone's Q3 net loss widens
Overview
NurExone reports Q3 2025 net loss of $1.47 mln, an increase from Q3 2024
Company raised C$3.2 mln from warrant exercises to support working capital
New U.S. and Israel patents granted for exosome production process
Outlook
Company did not provide specific financial guidance
Result Drivers
WARRANT EXERCISE - Co raised C$3.2 mln from accelerated warrant exercises to support working capital
R&D EXPENSES: Net R&D expenses were $0.70 million in Q3 2025, compared to $0.50 million in Q3 2024
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Net Income |
| -$1.47 mln |
|
Analyst Coverage
Wall Street's median 12-month price target for Nurexone Biologic Inc is C$3.06, about 76.8% above its November 27 closing price of C$0.71
Press Release: ID:nGNX3RRFC4
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
Related Articles
Global AI Models Enter a New Wave of Upgrades Beyond Gemini 3
In addition to the Gemini3, large-scale models worldwide are also receiving a collective upgrade.
Google Strikes Back: With Gemini 3 Dominating the Charts, Is Nvidia Still the Only Winner?
Gemini 3 Pro performance and TPU's cost advantage shatter the 'Google is doomed' narrative. This analysis details Google's full vertical integration, its resistance to the Nvidia Tax, and YouTube’s strategic data moat. Is GOOGL poised to dominate the AI endgame?
The U.S. Dollar Index Is the Key Driver of Gold Prices: Where Are the Dollar and Gold Headed Next?
TradingKey - The strength or weakness of the U.S. Dollar Index stands as the core determinant shaping gold's trajectory.
Alibaba FY2026Q2 Earnings Preview: The Great Pivot from E-Commerce Giant to AI Powerhouse
TradingKey - As Alibaba's earnings approach, one question dominates: Can AI and quick commerce justify sacrificing profits now for future dominance? Preview how the RMB 50 billion quick commerce push, 35.8% AI cloud share, and fierce competition could decide if BABA's 88% rally holds.
U.S. September Nonfarm Payrolls: Two-Scenario Analysis, Will U.S. Stocks Diverge in Short-Term and Medium-to-Long-Term Trends?
TradingKey - This paper conducts an analysis of the U.S. September nonfarm payroll data and the subsequent employment market through two scenario-based assessments, alongside a short-term and medium-to-long-term outlook for U.S. stocks.
